DormioVita

Manuel Krispin, PhD
Email: mkrispin@dormiovita.com
Phone: +1 302 203 - 9916

Every night in the US, more than 2. 5 million children struggle to breathe while sleeping.

Night after night, families are left worried and uncertain.

This is not just restless sleep. It could be obstructive sleep apnea (OSA)

Wired, Anxious, and Awake: The Reality of an Overnight Sleep Study

- Gold standard polysomnography (PSG), costly and limited access.
- Families wait over 6 months for a stressful, overnight sleep lab-based study → not scalable
- The most common first-line treatment, tonsil removal, leaves 30% of children with OSA, repeating the cycle.

The Solution: A simple blood test as the first step toward faster treatment for children.

DormioVita

Measuring Symptoms vs. Measuring Disease

At Home Sleep Devices & Wearables

✗ Track only indirect symptoms → **not validated for pediatric OSA**

✗ Dependent on child behavior and compliance → often inconclusive

✗ Limited to home symptom tracking, not clinical testing in children

Blood Based Marker Panel

✓Directly measures disease biology (OSA-linked RNA markers)

✓ Works independent of child behavior/device fit, producing objective results

✓Backed by published research, with clinical validation planned

Market Opportunity U.S.



2.5M children
suffering with sleep-disordered breathing

225,000 children
referred each year for suspected OSA

Projected: 90,000 children
tested annually

Path to FDA Approval and Reimbursement by 2029



We will pursue regulatory, clinical and payer coverage in parallel to establish commercial readiness.

DormioVita's Experienced Team & Advisors

Manuel Krispin, PhD
Founder & CEO

David Gozal, MD, MBA, PhD (Hon)
Co-Inventor, Pediatric Pulmonologist and Pediatric Sleep Expert

Rene Cortese, PhD
Co-Inventor, Scientific Advisor
Associate Professor, University of Kansas Medical Center

Christopher Thibodeau
Advisor, Commercial & Reimbursement Strategy

Chris Hobson, PhD
Strategic Advisor, Innovation

Join our mission to bring timely and accurate answers to children and families.

Raising $1.2M Pre-seed Round

Key milestones over the next 18 months:

- Independent clinical validation
- Transfer assay onto ‘sample-to-answer’ platform
- Initiate FDA pre-submission and regulatory path alignment
- Publish cost-effectiveness analysis to support reimbursement

Manuel Krispin, PhD
Email: mkrispin@dormiovita.com
Phone: +1 302 203 - 9916

DormioVita